Dr Angelika Bickel
01.01.2021
First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor
Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. J Cancer Res Ther 2021; 17:276-278.
01.01.2021First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor
01.01.2021J Cancer Res Ther 2021; 17:276-278
Bickel Angelika, Diem Stefan, Flatz Lukas, Stinn Björn, Siano Marco
Weiter
19.08.2016
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer 2016; 16:656.
19.08.2016Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
19.08.2016BMC cancer 2016; 16:656
Bickel Angelika, Koneth Irene, Enzler-Tschudy Annette, Neuweiler Jörg, Flatz Lukas, Früh Martin
Weiter